share_log

Aier Eye Hospital Group Co., Ltd.'s (SZSE:300015) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Aier Eye Hospital Group Co., Ltd.'s (SZSE:300015) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

愛爾眼科醫院集團股份有限公司(SZSE:300015)的基本面看起來非常強勁:市場對該股錯了嗎?
Simply Wall St ·  07/12 21:06

Aier Eye Hospital Group (SZSE:300015) has had a rough three months with its share price down 12%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes, the company is worth looking at. Specifically, we decided to study Aier Eye Hospital Group's ROE in this article.

愛爾眼科醫院集團(SZSE:300015)在過去的三個月裏股價下跌了12%。但是,仔細研究其健康的財務狀況可能會讓您再次思考。鑑於基本面通常驅動長期市場結果,因此值得關注該公司。本文着重研究了愛爾眼科醫院集團的roe。

Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.

淨資產收益率(ROE)是衡量公司增值和管理投資者資金有效性的測試。換句話說,它是一種盈利能力比率,用於衡量公司股東提供的資金回報率。

How Do You Calculate Return On Equity?

怎樣計算ROE?

ROE can be calculated by using the formula:

淨資產收益率可以使用以下公式進行計算:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

淨資產收益率 = 淨利潤(從持續經營中獲得)÷ 股東權益

So, based on the above formula, the ROE for Aier Eye Hospital Group is:

因此,根據上述公式,Aier Eye Hospital Group的roe爲:

18% = CN¥3.7b ÷ CN¥21b (Based on the trailing twelve months to March 2024).

18%= CN ¥37億 ÷ CN ¥210億(基於2024年3月的最近十二個月)。

The 'return' is the profit over the last twelve months. So, this means that for every CN¥1 of its shareholder's investments, the company generates a profit of CN¥0.18.

“回報”是過去十二個月的利潤。這意味着,對於其股東投資的每CN¥1,該公司可以創造CN¥0.18的利潤。

What Is The Relationship Between ROE And Earnings Growth?

既然我們已經確定ROE是一種有效的利潤生成標準,用於評估公司未來的盈利能力,我們現在需要評估公司“保留”爲未來增長而重新投資的利潤多少,這使我們對公司的增長潛力有了一個了解。一般而言,在其他條件相等的情況下,ROE和利潤留存高的公司,增長率比沒有這些屬性的公司要高。

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

我們已經確定ROE是衡量公司未來盈利能力的有效指標。基於公司選擇再投資或“留存”利潤的比例,我們可以評估公司未來生成利潤的能力。其他條件相同的情況下,具有更高淨資產收益率和更高利潤留存率的公司通常比沒有這些特點的公司增長率更高。

A Side By Side comparison of Aier Eye Hospital Group's Earnings Growth And 18% ROE

愛爾眼科醫院集團收益增長和18%roe的並排比較

To begin with, Aier Eye Hospital Group seems to have a respectable ROE. On comparing with the average industry ROE of 6.4% the company's ROE looks pretty remarkable. Probably as a result of this, Aier Eye Hospital Group was able to see an impressive net income growth of 22% over the last five years. We reckon that there could also be other factors at play here. For example, it is possible that the company's management has made some good strategic decisions, or that the company has a low payout ratio.

首先,愛爾眼科醫院集團似乎具有可敬的roe。與行業平均roE6.4%相比,該公司的roe看起來相當出色。可能正因爲如此,愛爾眼科醫院集團在過去五年中實現了22%的淨收入增長。我們認爲這裏還可能有其他因素。例如,公司的管理層可能已經做出了一些好的戰略決策,或者該公司的支付比率較低。

As a next step, we compared Aier Eye Hospital Group's net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 4.2%.

作爲下一步,我們將愛爾眼科醫院集團的淨收入增長與該行業進行了比較,並且令人高興的是,我們發現該公司的增長率高於該行業平均增長率4.2%。

big
SZSE:300015 Past Earnings Growth July 13th 2024
SZSE:300015過去的收益增長2024年7月13日

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. What is 300015 worth today? The intrinsic value infographic in our free research report helps visualize whether 300015 is currently mispriced by the market.

評估公司價值的基礎在很大程度上與其收益增長有關。投資者了解市場是否已經定價了公司的預期收益增長(或下降)很重要。然後,這有助於他們確定股票的未來是光明還是黯淡。300015今天值多少?我們免費研究報告中的內在價值信息圖幫助您了解300015當前是否被市場錯誤定價。

Is Aier Eye Hospital Group Efficiently Re-investing Its Profits?

愛爾眼科醫院集團有效地再投資其利潤嗎?

The three-year median payout ratio for Aier Eye Hospital Group is 28%, which is moderately low. The company is retaining the remaining 72%. By the looks of it, the dividend is well covered and Aier Eye Hospital Group is reinvesting its profits efficiently as evidenced by its exceptional growth which we discussed above.

愛爾眼科醫院集團的三年中位數支付比率爲28%,相對較低。公司保留其餘72%。看起來,紅利得到了充分覆蓋,並且愛爾眼科醫院集團正在有效地再投資其利潤,正如我們上面所討論的一樣,這也反映在其非凡的增長上。

Moreover, Aier Eye Hospital Group is determined to keep sharing its profits with shareholders which we infer from its long history of paying a dividend for at least ten years. Our latest analyst data shows that the future payout ratio of the company is expected to rise to 38% over the next three years. Despite the higher expected payout ratio, the company's ROE is not expected to change by much.

此外,愛爾眼科醫院集團決心繼續與股東共享利潤,這是我們從其至少十年的支付股息的歷史中推斷出的。我們最新的分析師數據顯示,該公司未來三年的紅利支付比率預計將上升至38%。儘管預期的支付比率較高,但公司的roe不太可能發生太大變化。

Summary

總的來說,我們對偉明環保的表現非常滿意。具體而言,我們喜歡公司以高回報率再投資了其利潤的很大一部分。當然,這導致公司的收益大幅增長。但是,最新的行業分析師預測表明,該公司的收益預計將加速增長。

Overall, we are quite pleased with Aier Eye Hospital Group's performance. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. On studying current analyst estimates, we found that analysts expect the company to continue its recent growth streak. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.

總的來說,我們對愛爾眼科醫院集團的表現感到非常滿意。特別是,看到公司大力投資業務,並且隨着高收益率,公司的收益增長相當可觀。通過研究當前的分析師估計,我們發現分析師預計公司將繼續保持其最近的增長趨勢。要了解有關公司未來收益增長預測的更多信息,請參閱本公司的分析師預測。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關注內容?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋? 對內容感到擔憂? 請直接與我們聯繫。 或者,發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論